VSee Health (VSEE) AI Stock Analysis

• Market Cap: $11.84M
• Dividend Yield: N/A
• Average Volume (3M): 158.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.16
• Revenue Growth: N/A
• EPS Growth: -280.85%
• Country: US
• Employees: 2
• Sector: Financial
• Sector Strength: 70
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -4.47
• Shares Outstanding: 16,422,690
• 10 Day Avg. Volume: 117,106
• 30 Day Avg. Volume: 158,901
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 2.57
• Enterprise Value/Revenue: 2.92
• Enterprise Value/Gross Profit: 4.24
• Enterprise Value/Ebitda: -0.52
• 1Y Price Target: $0.50
• Price Target Upside: -28.57% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0

• Rating: 38 Underperform
• Price Target: $0.50 ▼(-28.57% Downside)

VSee Health's overall stock score is heavily impacted by financial instability and the risk of Nasdaq delisting. While there is some revenue growth, the negative equity, poor valuation, and bearish technical indicators contribute to a low score.

Positive Factors

Revenue Growth

The strong revenue growth indicates a positive trajectory for VSee Health, suggesting expanding market reach and increased adoption of its telehealth solutions.

Cash Flow Improvement

Improvement in free cash flow growth enhances VSee Health's ability to reinvest in business operations, supporting long-term growth and financial stability.

High Gross Profit Margin

A high gross profit margin indicates efficient cost management and strong pricing power, which are crucial for sustaining profitability in the long term.

Negative Factors

Nasdaq Delisting Risk

The risk of Nasdaq delisting could limit market access and liquidity, negatively impacting investor confidence and the company's ability to raise capital.

Negative Equity

Negative equity reflects financial instability, posing risks to long-term viability and limiting the company's ability to secure financing.

Profitability Challenges

Ongoing profitability challenges indicate operational inefficiencies, which could hinder VSee Health's ability to achieve sustainable growth and financial health.

VSee Health Business Overview & Revenue Model

Company Description

VSee Health, Inc. provides telehealth care solutions. The company offers iDoc Telehealth solutions that treat and coordinate care for acutely ill patients in the neurointensive care, cardiac intensive care, and intensive care units for stroke, spinal cord, brain trauma, and other neurological conditions. Its telehealth platform provides a set of building blocks to solve needs of clients. VSee Health, Inc. is headquartered in Newton, Massachusetts.

How the Company Makes Money

VSee generates revenue through multiple streams, primarily by offering subscription-based services to healthcare providers and organizations. The company charges clients a monthly or annual fee for access to its telehealth platform, which can vary based on the features and number of users. Additionally, VSee may earn revenue through transaction fees for specific telehealth services, as well as through partnerships with healthcare systems and organizations that integrate its technology into their operations. Significant partnerships with hospitals, clinics, and telehealth networks further enhance its market reach and contribute to its earnings.

VSee Health Financial Statement Overview

Summary

VSee Health shows strong revenue growth but faces significant profitability and financial stability challenges. Negative equity and high leverage are major risks, despite improvements in free cash flow.

Income Statement

VSee Health has shown strong revenue growth of 29.22% in the latest year, indicating a positive trajectory. However, the company is struggling with profitability, as evidenced by negative net profit margins and EBIT margins. The gross profit margin remains healthy at 68.87%, but the significant negative EBIT and net income highlight ongoing operational challenges.

Balance Sheet

The balance sheet reveals a concerning financial structure with a negative stockholders' equity, leading to a high and negative debt-to-equity ratio. This indicates potential financial instability. The return on equity is extremely high due to the negative equity, which is misleading. The company needs to address its equity position to improve financial health.

Cash Flow

Cash flow analysis shows a substantial improvement in free cash flow growth, up by 157.14%. However, operating cash flow remains negative, and the operating cash flow to net income ratio is unfavorable. The free cash flow to net income ratio is slightly above 1, suggesting some efficiency in converting net income to free cash flow.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.42M	5.84M	6.38M	7.34M	6.80M
Gross Profit	7.18M	3.91M	4.84M	5.92M	5.46M
EBITDA	-57.75M	-2.24M	-2.93M	-280.70K	-45.03K
Net Income	-57.70M	-3.45M	-836.21K	475.90K	258.88K
Balance Sheet
Total Assets	19.99M	830.79K	2.61M	1.94M	2.73M
Cash, Cash Equivalents and Short-Term Investments	326.12K	118.73K	230.66K	346.44K	775.24K
Total Debt	9.55M	543.00K	517.13K	0.00	133.08K
Total Liabilities	20.01M	4.24M	2.61M	1.01M	2.11M
Stockholders Equity	-18.49K	-3.09M	360.72K	1.20M	614.49K
Cash Flow
Free Cash Flow	-5.84M	-636.93K	-1.45M	-459.80K	789.12K
Operating Cash Flow	-5.79M	-632.60K	-1.45M	-459.80K	789.12K
Investing Cash Flow	-26.14K	-4.33K	110.12M	-116.73M	0.00
Financing Cash Flow	6.02M	525.00K	710.00K	31.00K	-83.67K

VSee Health Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VSEE, the sentiment is Negative. The current price of 0.7 is below the 20-day moving average (MA) of 0.74, below the 50-day MA of 1.05, and below the 200-day MA of 1.27, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 36.78 is Neutral, neither overbought nor oversold. The STOCH value of 66.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VSEE.

VSee Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OPRX	68 Neutral	$349.58M	―	-8.21%	―	25.90%	46.13%
Sector *	68 Neutral	$18.10B	11.66	9.93%	3.76%	9.70%	1.14%
EVH	51 Neutral	$1.09B	―	-13.38%	―	-6.71%	-71.40%
TDOC	51 Neutral	$1.37B	―	-14.18%	―	-2.57%	79.86%
AMWL	50 Neutral	$109.03M	―	-38.52%	―	5.83%	61.94%
VSEE	38 Underperform	$11.84M	―	-3190.66%	―	―	-280.85%
EUDA	―	$43.47M	―		―	―	―

VSee Health Corporate Events

VSee Health Appeals Nasdaq Delisting Notice

On August 5, 2025, VSee Health, Inc. received a notice from Nasdaq indicating a potential suspension of its stock and warrants due to non-compliance with listing rules, including failure to timely file financial reports and insufficient stockholders’ equity. The company is appealing the decision and plans to address these deficiencies in a hearing scheduled for September 9, 2025. If the appeal is unsuccessful, VSee Health’s securities may be delisted, potentially limiting market access and affecting trading prices.

VSee Health Faces Nasdaq Delisting Notice

VSee Health, Inc. received a notice from Nasdaq on August 20, 2025, for non-compliance with listing rules due to delayed filing of required reports with the SEC. The company is scheduled for a hearing on September 9, 2025, to appeal the decision to delist its stock and warrants from Nasdaq, with trading expected to move to OTC Markets if delisting proceeds. The potential delisting could limit market accessibility for shareholders and affect stock prices.